[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350763-105":59,"doc-detail-350763-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","associations-between-legacy-and-emerging-per-and-polyfluoroalkyl-substances-pfas-bioaccumulation-and-clinicopathological-characteristics-in-breast-cancer","Associations between Legacy and Emerging Per and Polyfluoroalkyl Substances (PFAS) Bioaccumulation and Clinicopathological Characteristics in Breast Cancer","","Per and polyfluoroalkyl substances (PFAS) are persistent endocrine-disrupting environmental contaminants with carcinogenic potential, yet their bioaccumulation patterns and clinical meaning in breast cancer remain insufficiently characterized. This preliminary study measured absolute concentrations of 33 PFAS congeners in paired tumor and adjacent non-tumor tissues from 11 patients using LC–MS/MS. Several congeners showed higher tumor burden after multiple-testing correction, and PFAS levels correlated with clinicopathological features and predicted breast-cancer pathways, including PPAR signaling. Because the cohort is small and targets are computationally predicted, results require validation in larger studies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/associations-between-legacy-and-emerging-per-and-polyfluoroalkyl-substances-pfas-bioaccumulation-and-clinicopathological-characteristics-in-breast-cancer/350763/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/associations-between-legacy-and-emerging-per-and-polyfluoroalkyl-substances-pfas-bioaccumulation-and-clinicopathological-characteristics-in-breast-cancer/350763.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":56},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main aim of this PFAS study in breast cancer?","Question",{"text":112,"@type":113},"To quantify PFAS bioaccumulation in tumor versus adjacent non-tumor tissues and assess correlations with clinicopathological characteristics.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were PFAS congeners measured and which tissues were compared?",{"text":117,"@type":113},"Absolute concentrations of 33 PFAS congeners were measured by LC–MS/MS in paired tumor and adjacent non-tumorous tissues from 11 breast cancer patients.",{"name":119,"@type":110,"acceptedAnswer":120},"Which PFAS signals were most notable in tissue distribution and statistical testing?",{"text":121,"@type":113},"Six compounds had detection rates above 40%, and multiple congeners showed higher tumor concentrations; enrichment for HFPOTA, PFNA, and PFUnDA remained significant after Benjamini–Hochberg correction.",{"name":123,"@type":110,"acceptedAnswer":124},"What biological and clinical associations were suggested by the findings?",{"text":125,"@type":113},"Bioinformatic analyses indicated predicted PFAS–breast cancer shared targets enriched in PPAR signaling, lipid metabolism, and steroid hormone biosynthesis, and PFOS concentrations related descriptively to molecular subtype and Ki-67 proliferation.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},350763,1790146751,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":56,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 18 August 2026  \nDOI 10.3389/fpubh.2026.1879297  \nOPEN ACCESS  \nEDITED BY  \nChristian Ebere Enyoh, Saitama University, Japan  \nREVIEWED BY  \nAkash Phillip,  \nIIMT University, India Sohel Rana,  \nSaitama University, Japan  \n*CORRESPONDENCE  \nMingqing Zhang  \n [zmq@nankai.edu.cn](zmq@nankai.edu.cn)[ ](zmq@nankai.edu.cn)Chong Chen  \n [chongchen@tmu.edu.cn](chongchen@tmu.edu.cn)[ ](chongchen@tmu.edu.cn)Dongzhi Hu  \n [tchdz@163.com](tchdz@163.com)[ ](tchdz@163.com)Feng He  \n [heaven@tju.edu.cn](heaven@tju.edu.cn)[ ](heaven@tju.edu.cn)Jie Hao  \n [haojie1215@126.com](haojie1215@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 12 May 2026  \nREVISED 25 July 2026  \nACCEPTED 31 July 2026  \nPUBLISHED 18 August 2026  \nCITATION  \nSun B, Gao Z, Liu X, Liu G, Wang S, Liu J, Wang J, Zhang H, Zhang M, Chen C, He F, Hu D and Hao J (2026)  \nAssociations between legacy and emerging per and polyfluoroalkyl substances (PFAS) bioaccumulation and clinicopathological characteristics in breast cancer.  \nFront. Public Health 14:1879297.  \ndoi: 10.3389/fpubh.2026.1879297  \nCOPYRIGHT  \n© 2026 Sun, Gao, Liu, Liu, Wang, Liu, Wang, Zhang, Zhang, Chen, He, Hu and Hao. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAssociations between legacy and emerging per and polyfluoroalkyl substances (PFAS) bioaccumulation and clinicopathological characteristics in breast cancer  \nBei Sun 1 , 2†, Zhanhua Gao3†, Xiyue Liu3†, Gexue Liu3†,  \nShoujun Wang3†, Jinpu Liu3, Junyi Wang3, Haiyang Zhang3, Mingqing Zhang3*, Chong Chen3*, Feng He 1*, Dongzhi Hu3* and Jie Hao3*  \n1Institute of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China, 2Department of Pharmacy, The Second Hospital of Tianjin Medical University, Tianjin, China, 3Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China  \nInroduction: Per and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants with endocrine-disrupting and carcinogenic potential. However, their bioaccumulation profiles and clinical relevance in human breast cancer remain largely unexplored.  \nMethods: In this preliminary study we quantified the absolute concentrations of 33 PFAS congeners (ng/g) in paired tumour and adjacent non-tumorous tissues from 11 breast cancer patients (n = 11) using LC–MS/MS to evaluate their tissue distribution and clinical correlations.  \nResults: The detection rates for six compounds (HFPOTA, PFOA, PFNA, PFUnDA, PFOS, and 6:2Cl-PFESA) were greater than 40% . In paired samples, several congeners showed higher concentrations in tumour than in adjacent non-tumoroustissue; using a two-sided exact Wilcoxon signed-rank test with Hodges–Lehmann effect sizes, tumour enrichment remained significant after Benjamini–Hochberg correction for HFPOTA (q = 0.041), PFNA (q = 0.047) and PFUnDA (q = 0.047) . HFPOTA showed by far the highest tissue burden (median 654 ng/g) . Clinically, PFOS concentrations were descriptively higher in Luminal B than in Luminal A tumours and were positively correlated with the proliferation marker Ki-67; a high 6:2Cl-PFESA–PR rank correlation was observed in four samples but was not statistically significant on the raw p-value (p ≈ 0.051) and is exploratory. Bioinformatic analyses indicated that computationally predicted shared target genes of PFAS and breast cancer are enriched in the PPAR signaling pathway, lipid metabolism, and steroid hormone biosynt","cbCaiaA4qsSaXWOH","https://ap.wps.com/l/cbCaiaA4qsSaXWOH","pdf",4827891,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What was the main aim of this PFAS study in breast cancer?\",\"answer\":\"To quantify PFAS bioaccumulation in tumor versus adjacent non-tumor tissues and assess correlations with clinicopathological characteristics.\"},{\"question\":\"How were PFAS congeners measured and which tissues were compared?\",\"answer\":\"Absolute concentrations of 33 PFAS congeners were measured by LC–MS/MS in paired tumor and adjacent non-tumorous tissues from 11 breast cancer patients.\"},{\"question\":\"Which PFAS signals were most notable in tissue distribution and statistical testing?\",\"answer\":\"Six compounds had detection rates above 40%, and multiple congeners showed higher tumor concentrations; enrichment for HFPOTA, PFNA, and PFUnDA remained significant after Benjamini–Hochberg correction.\"},{\"question\":\"What biological and clinical associations were suggested by the findings?\",\"answer\":\"Bioinformatic analyses indicated predicted PFAS–breast cancer shared targets enriched in PPAR signaling, lipid metabolism, and steroid hormone biosynthesis, and PFOS concentrations related descriptively to molecular subtype and Ki-67 proliferation.\"}]","Associations between Legacy and Emerging Per and Polyfluoroalkyl Substances (PFAS) Bioaccumulation and Clinicopathological Characteristics in Breast Cancer | PDF",1790090959,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/206675310caf45fbfbb352947096608c.webp",983,1390,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/241d7527b4f0174b198bdc9c390fde5c.webp",982,1388,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91a360da43dc9da7253f5b98fddcb684.webp",981,1387,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23fd188cfaccc1670f165aa794fdfe39.webp",980,1385]